The Walgreens Boots Alliance NOligarchy Profile
A
V
O
I
D
NOligarchy Score
24.6
/ 100
walgreens.com
0
Ranked in
Pharmacy & Drugstore Chains
#7
Owned by Sycamore Partners (private equity). Our score doesn't yet fully measure what private-equity owners take out of the companies they own.
Walgreens Boots Alliance scores 24.62 on the NOligarchy scale — a number driven by a near-zero compliance record, a nearly $5 million federal lobbying footprint, and a CEO whose three-year average compensation package ran 452 times what the median worker earned.
Current Pillar Scores
Owned by Sycamore Partners (private equity). Its own lobbying and pay data are not added here; we count what we can document the firm taking out, such as debt deals and payouts.
Political Access
17.9
Wealth Extraction
46.6
Playing by the Rules
1.3
Score history — 24 quarters
Tier bands show where each quarter's score falls — no numeric y-axis needed. The dashed ring marks the year-over-year comparison point. Tap any quarter but the first to see its pillar breakdown.
The Pillar Grades:
•
Political Access Grade: 17.9/100. Walgreens funneled $4.97 million into federal lobbying and another $209,500 through its Political Action Committee (PAC) from Q4 2024 through Q3 2026, deploying a web of outside firms and former government insiders to shape rules on pharmacy reimbursement, drug pricing, and Medicare policy.
•
Wealth Extraction Grade: 46.61/100. The company’s CEO averaged more than 452 times the median worker’s earnings over three years, while $1.329 billion left the company in dividends and buybacks in a single fiscal year.
•
Playing by the Rules Grade: 1.25/100. Walgreens Boots Alliance carries $513 million in regulatory penalties across 23 cases — the heaviest fine total among all five companies in its federal industry classification, driven by a $300 million controlled-substances settlement and nearly $100 million in fraudulent billing claims.
The Sector Context: Walgreens Boots Alliance ranks 4th out of 5 among companies sharing its federal industry classification (Health and personal care retailers). The sector average NOligarchy score is 40.8; Walgreens’ 24.62 falls well below that already-imperfect benchmark. For higher-scoring alternatives in this space, see the Better Alternatives section below.
The Bottom Line: A $513 Million Fine Tab, $1.3 Billion to Shareholders — Workers Got $698
Walgreens Boots Alliance reported $147.7 billion in annual revenue — a scale that puts it among the largest retail pharmacy operations on earth — yet its 313,941 workers earned a median salary of $32,958 a year while the company dispatched $1.329 billion to shareholders in a single fiscal year. It channeled more than $5.18 million into federal lobbying and PAC contributions from Q4 2024 through Q3 2026 (8 quarters — the two-year tracking period), targeting pharmacy reimbursement, Medicare policy, and drug-pricing rules. At the same time, regulators and courts extracted more than $513 million in penalties for failures ranging from opioid dispensing breakdowns to consumer fraud — a fine total more than 2,600 times the $192,187 in public subsidies governments handed the company during the same span.
$5.2 million in political spending
Two-story house · 12 ft
1.6×
Stacked as $100 bills, Walgreens Boots Alliance's $5.2 million in political spending rises 19 feet — 1.6× the height of a two-story house.
Spending to Hold the Line on Drug Reimbursement
From Q4 2024 through Q3 2026, Walgreens poured $4.97 million into federal lobbying and an additional $209,500 through its PAC, bringing total political outlays to more than $5.18 million. That investment secured access at every level of federal government: its lobbyists engaged the House of Representatives 110 times and the Senate 107 times, while also reaching the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the Executive Office of the President.
The lobbying filings leave no mystery about the stakes. Pharmacy issues topped the docket with 31 entries, followed by Medicare and Medicaid with 30, and general health issues with 22. For a company that fills prescriptions at thousands of retail locations, government reimbursement rates are one of the most consequential levers in the business. Filings cited the Inflation Reduction Act of 2022 (P.L. 117-169) as it relates to pharmacy and Medicare reimbursement, and repeatedly referenced the Combatting Organized Retail Crime Act (H.R. 2853/S. 1404) — a bill that would create new federal tools to address theft at retail locations — appearing across both consumer issues and law enforcement filings.
Thirteen entries addressed taxation, including the Work Opportunity Tax Credit and issues around corporate net operating losses and earnings before interest, taxes, depreciation, and amortization — squarely tied to Walgreens’ balance sheet after years of financial strain. Five entries covered labor and antitrust matters under “health care and competition.”
Walgreens retained 11 outside lobbying firms, and 9 of those firms also represent other major corporations tracked in this database — a network that gives the company’s dollars a reach far beyond what any single filing suggests.
Shared Lobbying Exposure
Walgreens Boots Alliance
client
BALLARD PARTNERS
lobbying firm
Amazon.com Inc
also a client
Lego
also a client
Lenovo Group Limited
also a client
+5 more
clients
BROWNSTEIN HYATT FARBER SCHRECK, LLP also lobbies for AT&T, Alibaba Group Holding Limited, Apollo Global Management, Inc. +5 more
BGR GOVERNMENT AFFAIRS also lobbies for Alibaba Group Holding Limited, CVS Health Corporation, Kontoor Brands Inc +2 more
FORBES-TATE also lobbies for Shein, Sony, T-Mobile +2 more
S-3 GROUP also lobbies for LVMH Moet Hennessy Louis Vuitton Inc., Lego, Lowe's Companies Inc +2 more
+4 more shared firms
Why it matters: the same firm argues Walgreens Boots Alliance’s case and its rivals’ — one hire buys a web of shared access that can’t be seen from outside. This network worsens Walgreens Boots Alliance’s political-access score (see methodology for the exact factor).
Of the 98 lobbyists working these accounts, 58 had previously held government positions — senior roles at the Senate Finance Committee, HHS, CMS, the Executive Office of the President, and leadership offices in both chambers. More than half of Walgreens’ lobbyists arrived with a contacts list built inside the very institutions they are paid to influence.
The company’s PAC gave $83,000 to Democrats and $78,500 to Republicans — a nearly identical split that ensures access regardless of which party controls the chamber.
Walgreens Boots Alliance's PAC gave $83,000 to Democrats and $78,500 to Republicans — a 51.4% / 48.6% split that buys access to whichever party wins.
51.4%
48.6%
Democrats · $83,000
Republicans · $78,500
ACCESS-BUYER PENALTY APPLIED
A $15 Million Corner Office While Cashiers Earn $33,000
Walgreens Boots Alliance’s CEO pay ratio is 452:1, the 3-year average of Compensation Actually Paid, as disclosed in the SEC DEF 14A. The CEO’s three-year average package was about $14.9 million. The median Walgreens employee earned $32,958 — a salary that, divided across a standard work schedule, amounts to modest take-home pay for the pharmacists, technicians, cashiers, and distribution workers who keep the company’s thousands of locations running. For every dollar the median worker earned, the CEO pocketed 452 dollars.
The Shareholder Payout: In fiscal year 2024, Walgreens spent $69 million on stock buybacks — a deliberate reduction in shares outstanding that inflates per-share metrics and triggers executive performance bonuses — and paid out $1.26 billion in dividends, for a combined $1.329 billion returned to shareholders. That is a sum nearly equivalent to the annual earnings of more than 40,000 employees at the median wage. The buyback program extends back further: in FY2023, Walgreens spent another $150 million repurchasing its own shares.
The Missed Raise: The company made a deliberate choice. The money spent on buying back its own stock could have instead handed every single one of its 313,941 workers a $697.58 raise, spread across the last 2 years. Spread evenly across those 2 years, that works out to a $348.79 annual raise the company chose not to give.
EARNINGS STATEMENT — ANNUAL
EMPLOYEE: 1 of 313,941
Your share of the buyback
+$697.58
Per biweekly paycheck
+$13.42
SPENT INFLATING THE SHARE PRICE
Reported stock buybacks over the last 24 months: $219 million.
Spread across Walgreens Boots Alliance's 313,941 employees, its stock buybacks come to $697.58 per worker over the last 24 months of reported buybacks — about $13 on each of the 52 biweekly paychecks in that span.
Buybacks vs. Workers
What the buyback spend could have meant for 314K employees
Spent on buybacks
$219.0M
directed to shareholders
÷ 314K
workers
Per-worker raise
$698
per employee, 2-year total
Spread over those 2 years, that's a 1% annual raise on the median worker's $32,958 salary — money the company chose to send to shareholders instead.
The Dividend Factor: The data shows Walgreens did not have to choose between its investors and its workforce. It paid out $1.26 billion in traditional dividends and still layered buybacks on top. The company simply chose not to redirect any portion of that capital toward its front-line staff.
Executive Bonuses: The buyback mechanism and the 452:1 pay ratio are not coincidental. When a company reduces its share count through repurchases, Earnings Per Share rises automatically even if underlying profits are flat. That lift directly triggers performance bonuses for the same executives who approved the repurchases — the same executives sitting atop a 452:1 pay gap.
Fines Treated as a Business Expense
Between October 1, 2024, and September 30, 2026, Walgreens Boots Alliance accumulated $513,092,078 in regulatory penalties across 23 cases — the worst record among all five Health and personal care retailers tracked in this sector. Twenty-three cases spanning seven distinct offense categories is not a string of accidents. It is a pattern.
Regulatory Violations by Year
$512.8M · 10 cases
$460K
2024
1 case
$401.1M
2025
4 cases
$111.2M
2026
5 cases
The single largest hit arrived in 2025: a $300 million settlement with the Department of Justice (DOJ) over Controlled Substances Act violations — a federal finding that Walgreens had failed its obligations around dispensing controlled medications, opioids among them. That penalty alone equals nearly 60 years of the company’s current annual lobbying budget. The second-largest case, a $100 million consumer protection judgment via federal private lawsuit in 2026, was followed by a $97.8 million multi-state False Claims Act settlement in 2025 involving fraudulent government billing. Those three cases alone account for nearly $500 million of the total — the damage concentrated in the company’s core business of dispensing medications and billing government health programs. This two-year snapshot is just a fraction of Walgreens’ full docket on the source site.
The Subsidy Flip: While regulators were extracting hundreds of millions in penalties, state and local governments were simultaneously passing public money the other direction. Between October 1, 2024, and September 30, 2026, Walgreens received $192,187 in public subsidies, including a $90,000 tax credit from Arizona in 2025 and a $73,187 property tax abatement from a local government in Indiana in 2024. The same governments whose programs Walgreens billed fraudulently were handing it tax relief.